Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GP531 is a second-generation adenosine regulating agent. It is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | GP531 is a second-generation adenosine regulating agent. It is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia. |
In vivo | GP531 administration does not alter heart rate or mean aortic pressure but significantly improves left ventricular function by reducing end-diastolic pressure, volumes, and wall stress, while enhancing ejection fraction (EF), deceleration time of early mitral inflow velocity, and the slope of end-systolic pressure-volume relationship (PVR), without an increase in myocardial oxygen consumption (MVO2). At low doses, GP531 diminishes infarct size by 34% and the no-reflow zone extent by 31% compared to control, with high doses achieving reductions of 22% and 16%, respectively. Unlike adenosine, GP531 does not impact overall hemodynamics or blood flow, showcasing its efficacy in mitigating ischemic/reperfusion injury severity at lower doses without inducing adverse hemodynamic events such as bradycardia and hypotension. |
Molecular Weight | 347.37 |
Formula | C16H21N5O4 |
CAS No. | 142344-87-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (359.85 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GP531 142344-87-4 Neuroscience AChR GP-531 GP 531 inhibitor inhibit